Immix Biopharma Inc
IMMX6.740USD
+0.790+13.28%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
222.66MMarket Cap
LossP/E TTM
More Details of Immix Biopharma Inc Company
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
Immix Biopharma Inc Info
Ticker SymbolIMMX
Company nameImmix Biopharma Inc
IPO dateDec 16, 2021
CEORachman (Ilya)
Number of employees18
Security typeOrdinary Share
Fiscal year-endDec 16
Address11400 West Olympic Blvd.
CityLOS ANGELES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code90064
Phone18889581084
Websitehttps://immixbio.com/
Ticker SymbolIMMX
IPO dateDec 16, 2021
CEORachman (Ilya)
Company Executives of Immix Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gabriel Morris
Mr. Gabriel Morris
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Dr. Ilya Rachman, M.D., Ph.D.
Dr. Ilya Rachman, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Graham Ross
Dr. Graham Ross
Acting Chief Medical Officer, Head - Clinical Development
Acting Chief Medical Officer, Head - Clinical Development
--
--
Dr. Vladimir Torchilin, Ph.D.
Dr. Vladimir Torchilin, Ph.D.
Scientific Co-Founder
Scientific Co-Founder
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason Hsu, Ph.D.
Mr. Jason Hsu, Ph.D.
Independent Director
Independent Director
4.86M
--
Dr. Nancy T. Chang, Ph.D.
Dr. Nancy T. Chang, Ph.D.
Director
Director
421.94K
+421940.00%
Ms. Helen C. Adams, CPA
Ms. Helen C. Adams, CPA
Lead Independent Director
Lead Independent Director
174.75K
-227.00%
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
173.19K
+107035.00%
Ms. Jane M. Buchan, Ph.D.
Ms. Jane M. Buchan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Carey Ng, Ph.D.
Mr. Carey Ng, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
Other
78.17%
Shareholders
Shareholders
Proportion
Hsu (Jason)
9.32%
GKCC, LLC
6.21%
Rachman (Ilya M)
2.19%
The Vanguard Group, Inc.
2.10%
Ng (Carey)
2.00%
Other
78.17%
Shareholder Types
Shareholders
Proportion
Individual Investor
16.64%
Corporation
6.21%
Investment Advisor
5.13%
Investment Advisor/Hedge Fund
1.00%
Hedge Fund
0.21%
Venture Capital
0.07%
Research Firm
0.05%
Other
70.69%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
69
3.66M
7.01%
-955.81K
2025Q3
60
2.79M
8.55%
-1.92M
2025Q2
65
14.67M
52.67%
-1.12M
2025Q1
66
14.50M
53.34%
-1.02M
2024Q4
67
14.42M
52.43%
-1.29M
2024Q3
66
15.60M
56.77%
-243.92K
2024Q2
66
15.89M
59.32%
-308.72K
2024Q1
64
15.43M
77.52%
+5.90M
2023Q4
57
11.10M
62.12%
+3.00M
2023Q3
52
12.47M
73.23%
+2.63M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hsu (Jason)
4.86M
9.32%
--
--
Apr 22, 2025
GKCC, LLC
3.24M
6.21%
--
--
Apr 22, 2025
Rachman (Ilya M)
1.14M
2.19%
+746.00
+0.07%
Dec 10, 2025
The Vanguard Group, Inc.
730.16K
1.4%
+31.63K
+4.53%
Sep 30, 2025
Ng (Carey)
1.05M
2%
--
--
Apr 22, 2025
Bleichroeder LP
850.00K
1.63%
--
--
Sep 30, 2025
Chang (Nancy T)
421.94K
1.29%
+421.94K
--
Sep 08, 2025
Morris (Gabriel S)
586.41K
1.12%
+770.00
+0.13%
Dec 10, 2025
Geode Capital Management, L.L.C.
187.48K
0.36%
+26.36K
+16.36%
Sep 30, 2025
Adams (Helen C)
174.75K
0.34%
-227.00
-0.13%
Apr 22, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
